Insights
For the Second Time, AlignRx Makes the Inc. 5000, at No. 1411 in 2024
NEW YORK, August 15, 2024 – Inc. revealed today that AlignRx ranks No. 1411 on the 2024 Inc. 5000, its annual list of the fastest-growing
Evaluating the Efficacy and Value Proposition of Modern Diabetic Drugs- Insights for Brokers and Their Groups
As the pipeline of drugs for diabetes management continues to grow, benefit partners and advisors and the employer groups they serve are positioned to influence
Inside AlignRx: Employee Voices – Beckie Fenrick
Without a doubt, Beckie Fenrick is one of the go-to experts at AlignRx. Not only did she help build the business from the ground up,
A 5-point checklist for CAA compliance on Rx fiduciary oversight
Read an excerpt from an article by AlignRx COO Greg Sanderson that was recently published by Employee Benefit News.
Inside AlignRx: Employee Voices – Monica Gindhart
When we tell you that the AlignRx team is made up of experts, we mean it. Meet Monica Gindhart, AlignRx’s powerhouse Director of Account Management.
How employers and TPAs can ease the rising cost of specialty drugs with medical rebates
The pharmaceutical industry is in the middle of a dynamic shift that shows no signs of slowing down. Traditional drug pipelines are now increasingly dominated
Inside AlignRx: Employee Voices – Giorgio Vescera
If one thing is for sure, it’s that Giorgio Vescera is not your average consulting and analytics expert. With years of experience in pharmacy and
AlignRx Named Finalist for Best Places to Work in Western New York
Buffalo Business First has named AlignRx as a finalist for its 2024 Best Places to Work awards in the category for companies with 10-24 employees.
Stay Informed, Stay Ahead: CVS’s Transition from Humira to Biosimilars
CVS Formulary Change – What You Need to Know CVS Caremark has announced the removal of Humira from some of their formularies starting the second
Levemir Discontinuation: What You Need to Know
Novo Nordisk, a global healthcare company, has recently announced the discontinuation of Levemir, a long-acting insulin, in the United States. This significant development, announced in
Beyond Unit Cost: Evaluating Clinical Programs and Capabilities of PBMs
Read the full article by AlignRx COO Greg Sanderson on Employee Benefit News. Drug pricing is typically the main factor brokers and employer groups consider
Medicaid AMP Cap Removal: Market Changes & Rx Strategies Amidst New Provisions
The ever-evolving pharmaceutical landscape is no stranger to reforms and regulations. With the recent changes brought about by the American Rescue Plan (ARP) of 2021,
AlignRx President & CEO Kevin Kobielski Recognized in 2023 BenefitsPRO Luminaries Awards
BenefitsPRO, the No.1 provider of news, analysis and trends for benefits professionals, has announced its 2023 Luminaries Awards recognizing excellence in the benefits industry. Kevin
AlignRx Consulting Recognized on the 2023 Inc. 5000 List of Fastest Growing Companies
Inc. revealed today that AlignRx Consulting ranks No. 898 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. The
The Cost Implications of New Weight Loss Treatments for Plan Sponsors
See this article by AlignRx chief pharmacy officer Beckie Fenrick as it originally appeared in BenefitsPRO. With obesity rates in the United States having tripled
Why Carve-Outs Happen And How To Prevent Them
See this article by AlignRx CEO Kevin Kobielski as it originally ran in Healthcare Business Today. Carve-outs can be a thorn in the side of
Stay Connected
"(Required)" indicates required fields
